((自动化翻译由路透提供，请见免责声明 ))
12月30日 - ** 药物开发商Sangamo Therapeutics的股票 在延时交易中下跌47.4%，至1.23美元。
** SGMO称辉瑞 终止了 (link)，合作开发A型血友病基因疗法
** 公司与辉瑞公司的合作和许可协议将于 2025 年 4 月 21 日终止。
** 7月，辉瑞公司宣布了一项后期治疗研究的积极结果
** SGMO 表示，计划探索将 A 型血友病基因疗法商业化的所有方案，包括寻找新的合作伙伴
** 截至本周一收盘，SGMO股价累计上涨了330.7%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.